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Abstract 
 
Most inhaled nanomedicines in development are for the treatment of lung disease, yet little is 
known about their interaction with the respiratory tract lining fluids (RTLF). Here we combined 
the use of nano-silica, as a protein concentrator, with label-free snapshot proteomics (LC-
MS/MS; key findings confirmed by ELISA) to generate a quantitative profile of the RTLF 
proteome and provided insight into the evolved corona; information that may be used in future to 
improve drug targeting to the lungs by inhaled medicines. The asthmatic coronal proteome 
displayed a reduced contribution of surfactant proteins (SP-A and B) and a higher contribution of 
α1-antitrypsin. Pathway analysis suggested that asthmatic RTLFs may also be deficient in 
proteins related to metal handling (e.g. lactoferrin). This study demonstrates how the 
composition of the corona acquired by inhaled nanoparticles is modified in asthma and suggests 
depressed mucosal immunity even in mild airway disease. 
 
Short Communication 
 
Recent studies have shown how inhaled particle surfaces are modified when immersed in 
respiratory tract lining fluid (RTLF), becoming enriched with immune regulatory proteins, 
forming a corona that will be presented to the epithelium or phagocytic cells at the mucosal 
surface (1–4). This corona masks the original particle surface, changing its biological identity 
and potentially modifying the nature of the particles’ interaction with the lungs, e.g. toxicity, 
cellular uptake and, in the case of nanomedicines, therapeutic efficacy (2). An understanding of 
these interactions is therefore essential for the development of inhaled medicines and yet in 
contrast to the abundance of published work on intestinal fluids and their interactions with oral 
dosage forms in the field of oral biopharmaceutics (5), little work has focused on particle 
interactions with RTLF components, especially in the context of target lung diseases (1). In order 
to address this knowledge gap here we report the first visualization the corona formed in human 
RTLF and provided a detailed characterization of the biomolecular corona of particles in healthy 
versus asthmatic RTLFs.  
 
We studied the corona formed around silica nanoparticles (200 nm), a well characterized 
analytical standard (1), incubated in concentrated bronchoalveolar lavage (BAL) fluids obtained 
from atopic asthmatics (PC20 <8 mg/mL methacholine, treated with short-acting inhaled β2-
agonists on demand) and healthy control subjects.  For these studies we employed lavage fluids 
from 5 healthy volunteers (26.0 ± 2 years, 2M/3F) and 5 asthmatics (25 ± 6 years, 1M/4F, 
PC20=3.1 ± 2.6) concentrated back to their undiluted RTLF levels based on the ratio of lavage to 
plasma urea concentrations (a dilution factor to indicate the degree to which RTLF has been 
diluted in the recovered BAL fluid (6)), prior to pooling to provide a generic healthy and 
asthmatic sample. Experimental details are outlined in the supplementary material. It was 
important to control for age as a factor because of the known age-related changes in the lung, 
reflected functionally by decreased lung volumes, reduced mucociliary clearance and increased 
susceptibility to infection (7). 
 
Cryogenic transmission electron microscopy was employed to provide a direct visualization of 
corona formation around nanoscale particles after incubation in human RTLF from a healthy 
volunteer (Figure 1A). Electron micrographs revealed a clearly visible corona, appearing as a 
continuous layer of electron-dense coating with a thickness of 3-5 nm surrounding the particles. 
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This is in agreement with similar observations of corona formation around silica nanoparticles 
using Survanta
®
, an FDA approved bovine lung surfactant (1). The albumin-depleted coronal 
proteome was characterised by label-free quantitative liquid chromatography mass spectrometry 
(LC-MS/MS) using established methods (1), with over 400 coronal proteins identified, of which 
the most abundant 20 are highlighted in Table 1. For reasons of analytical sensitivity, it was 
necessary to deplete the lavage concentrates of albumin before incubation of the particles and 
proteomic characterization. Thus, the contribution of the most abundant RTLF protein to the 
corona is artificially under-represented in the analysis. We did not address the lipid components 
of the corona, although these are thought to be less discriminating (3, 4). 
 
Identified proteins were functionally classified using SwissProt and NCBI databases (Figure 
1B), with the abundance of individual proteins expressed as the percentage of the intensity of all 
the proteins identified. Using this approach a ~10% decrease in the contribution of innate 
immunity proteins was identified in the asthmatic corona, with surfactant protein A (SP-A) the 
most dysregulated (0.47-fold decrease; Figure 1Bi). A 5% decrease in the lipid 
metabolism/transport proteins was also observed in the asthmatic corona (Figure 1Bii). 
Conversely, the asthmatic corona was associated with a 5% increase in proteins involved in 
protease-antiprotease activity (Figure 1Biii), including a 1.7-fold increase of α1-antitrypsin. 
These differences in the coronal proteome reflect differences reported previously in the 
composition of BAL fluid from asthmatics. Wu et al. (8) and Cederfur et al. (9), using LC-
MS/MS, also found that the majority of the differentially expressed proteins in asthmatic RTLFs 
were associated with immune response (23%), lipid metabolism (12%) and proteolysis (9%). 
Thus, the coronal proteome appears to represent a concentrated fingerprint reflecting underlying 
protein composition of the host RTLF (10).  Differences between the corona formed in healthy 
and asthmatic RTLF were evaluated further using iPathwayGuide analysis to obtain biological 
insights by identifying the pathways/functions most impacted by the observed changes between 
the two groups.  This software analysis tool implements an ‘impact analysis’ approach, which 
takes into consideration not only the number of differentially expressed genes, or in this case 
proteins (i.e. enrichment analysis), but also topological information such as the direction and 
type of all signals in a pathway, and the position, role, and type of each protein (11).  Following 
quantile normalization and Benjamini–Hochberg correction for false discovery rate, we 
identified 26 differentially adhered proteins in the asthmatic corona (Figure 1C). Pathway 
analysis of these proteins demonstrated they were involved in immune system processes (Figure 
1Ci) and metal ion binding (Figure 1Cii), with lactoferrin contributing to both pathways.  
 
To evaluate the accuracy of this semi-quantification of coronal protein content, selected proteins 
were quantified by ELISA in lavage samples, both bronchial wash (BW) and BAL fluid from an 
expanded group of asthmatics (26.0 ± 6 years, 6M/10F, PC20=2.5 ± 2.6) and healthy (25 ± 2 
years, 11M/5F) subjects. Three proteins were examined Immunogobulin A (IgA, the major 
mucosal immunoglobulin, the levels of which appeared equivalent in the proteomic analysis), 
surfactant protein A (SPA, 0.47-fold decreased in asthmatics) and alpha-1-antitrypsin (1AT, 
1.74 fold increased in asthmatics) (Table 2). Although the differences in protein concentrations 
as determined by ELISA analysis did not attain statistical significance, the observed trends for 
reduced SP-A (P=0.06) and increased alpha-1-antitrypsin were consistent with the proteomic 
analysis. We extended the validation panel to include five further proteins, 4 selected of the basis 
of their high abundance within the coronal proteome (albumin, IgG, IgM and transferrin), and 
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the fifth due to the evidence of suppressed innate immune defense proteins (lysozyme). These 
data are summarized in Supplementary Table 1, together with the predicted fold changes 
obtained from the proteomic analysis. Of these proteins both transferrin and lysozyme appeared 
to most depressed within the mild asthmatic corona, 0.16 and 0.34-fold respectively. The more 
comprehensive ELISA data within the BAL fluid did not confirm this finding, but a significant 
(P<0.05) decrease in transferrin within the asthmatic BW samples was observed, with a trend 
(P=0.06) toward decreased lysozyme concentrations also within the proximal airway sample.  
Whilst the proteomic and ELISA results were not wholly concordant, these data overall, together 
with the pathway analysis, could be suggestive of depressed innate immune defense in mild 
asthmatics. Since the deficiencies in immune proteins identified within the asthmatic RTLF may 
increase susceptibility to microbial infection (12), lipopolysaccharide (LPS) levels were 
quantified to provide a proxy measure of bacterial load within the airway (see supplementary 
material). BAL fluid LPS activity was found to be 1.98-fold higher in asthmatics compared to 
healthy subjects, but did not attain statistical significance (Table 2). In contrast, a significant 6.6-
fold increase in LPS was noted in the more proximal BW sample from the asthmatics  (P<0.05).  
 
These data provide a detailed molecular characterization of the asthmatic coronal proteome, with 
evidence of deficiencies in proteins involved in innate immunity, lipid metabolism/transport and 
metal handling. Our observations may raise concerns about the impact of proposed therapeutic 
inhaled nanomedicines on innate immunity in the lung. The mechanism we have employed here 
to concentrate RTLF proteins, for characterisation purposes, may in vivo result in an unwanted 
sequestration of RTLF proteins. Axiomatically, the adsorption of proteins that trigger 
phagocytosis of a particle provides a clearance-promoting mechanism.  SP-A binding has been 
shown to trigger the uptake of particles in murine alveolar macrophages (13, 14), thus its reduced 
presence in the asthmatic corona may impair bacterial clearance. Similarly, the formation of the 
particle corona may lead to local depletion of innate immunity proteins at the surface of the 
lungs. Thus whilst the formation of the corona may modify particle clearance (15–17) thereby 
affecting drug disposition in the lungs, it may also increase the susceptibility of the airway to 
infection. Consistent with this, exposure to ultrafine carbon black particles has been shown to 
increase the susceptibility of the lung to both bacterial (18) and viral infections (19) in vivo.  
Susceptibility to infection has also been reported in populations exposed to cigarette smoke (20) 
combustion-derived air pollution (21) and occupational aerosols (22), This therefore raises the 
question as to whether inhaled slowly disintegrating nanoscale drug formulations may have 
adverse effects on immunity in the lung, especially with regular use. Such considerations do not 
apply to current inhaled medicines which exist transiently, if at all, in solid particle form in 
RTLF, although interestingly studies have demonstrated an increased risk of pneumonia in 
COPD patients using poorly soluble inhaled corticosteroids (23, 24). It is clearly important to 
understand particle-RTLF interactions and further work is needed in this area focused on 
relevant patient groups. 
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Table 1: The 20 most abundant proteins (in rank order) based on the mean intensity of the three major precursor ions 
identified in the SiO2 corona evolved after a 1 hour incubation in concentrated lavage pooled from healthy and asthmatic 
subjects. For each protein in the healthy corona, the ranking in terms of abundancy in the asthmatic group is provided (and vice 
versa).  Albumin is highlighted as the signal reflects the residual contribution after pre-depletion of albumin (the most abundant 
protein in RTLF) to enable identification of other proteins. 
 
 
Top 20 abundant proteins in the SiO2 corona 
 
Healthy Controls  Mild asthmatics 
Identified Proteins  
Relative rank 
in asthmatics  
Molecular 
Weight 
 
Identified Proteins  
Relative rank in 
healthy controls 
Molecular 
Weight 
   
 
   
Pulmonary surfactant-associated protein A2  1 26 kDa  Pulmonary surfactant-associated protein A2  1 26 kDa 
Serum albumin  2 69 kDa  Serum albumin  2 69 kDa 
Pulmonary surfactant-associated protein B  6 42 kDa  Alpha-1-antitrypsin  6 47 kDa 
Apolipoprotein A-I  9 31 kDa  Actin, cytoplasmic 1  5 42 kDa 
Actin, cytoplasmic 1  4 42 kDa  Ig alpha-1 chain C region  8 38 kDa 
Alpha-1-antitrypsin  3 47 kDa  Pulmonary surfactant-associated protein B  3 42 kDa 
Complement C3  7 187 kDa  Complement C3  7 187 kDa 
Ig alpha-1 chain C region  5 38 kDa  Complement C4-B  9 193 kDa 
Complement C4-B  8 193 kDa  Apolipoprotein A-I  4 31 kDa 
Hemoglobin subunit beta  12 16 kDa  Ig gamma-1 chain C region  11 36 kDa 
Ig gamma-1 chain C region  10 36 kDa  Polymeric immunoglobulin receptor  14 83 kDa 
Ig kappa chain C region  33 12 kDa  Hemoglobin subunit beta  10 16 kDa 
Ubiquitin-60S ribosomal protein L40  63 15 kDa  Fibronectin  22 263 kDa 
Polymeric immunoglobulin receptor  11 83 kDa  BPI fold-containing family B member 1  17 52 kDa 
Annexin A2  32 39 kDa  Napsin-A  16 45 kDa 
Napsin-A  15 45 kDa  Vitamin D-binding protein  56 53 kDa 
BPI fold-containing family B member 1  14 52 kDa  Alpha-enolase  18 47 kDa 
Alpha-enolase  17 47 kDa  Hemoglobin subunit alpha  45 15 kDa 
Apolipoprotein A-IV  34 45 kDa  Ig mu chain C region  27 49 kDa 
Ig gamma-3 chain C region  30 41 kDa  Glutathione S-transferase A2  94 26 kDa 
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Figure 1: Proteomic characterization of the hard corona formed around SiO2
 
particles incubated 
in concentrated bronchoalveolar lavage (BAL) fluids from healthy and mild asthmatic subjects. 
Panel A, cryoTEM image of SiO2 particle incubated in concentrated healthy human BAL fluid 
(see Supplementary Information Figure 1).  
Panel B, functional classification and relative abundance of proteins identified in the healthy and 
asthmatic corona; panel b1, most abundant innate immunity proteins within the corona of the two 
groups (proteins are identified using their gene IDs); panel b2, most abundant proteins in the 
protease/antiprotease group; panel b3, relative contribution of proteins involved in lipid 
metabolism and transport.  
Panel C illustrates the results of the iPathway analysis, with proteins with significant over, or 
under representation in the asthmatic corona (relative to the healthy; see Supplementary 
Information Figure 2) highlighted using a volcano plot; panel c1, illustrates perturbation of 
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proteins within the asthmatic corona related to immune system processes, using the conventional 
GO ontology; and panel c2, perturbations in proteins related to metal ion binding. 
 
Table 2: Selected protein concentrations and LPS activity quantified in bronchial wash and 
bronchoalveolar lavage fluid samples from expanded groups of healthy and asthmatic subjects. 
Data represent median values with the 25
th
 and 75
th
 percentiles, n=14-15 per group, reflecting the 
availability of lavage material. 
 
  Bronchial wash Bronchoalveolar lavage 
 Fold change  
(Proteomic analysis)  
Healthy Mild asthmatic Healthy Mild asthmatic 
      
SP-A (mg/ml) 0.47 1.04 (0.60-1.54) 0.46 (0.23-0.70) 1.00 (0.61-1.31) 0.64 (0.46-0.87) 
1AT (mg/ml) 1.74 0.68 (0.39-1.09) 0.38 (0.26-0.44) 0.94 (0.55-2.16) 1.55 (1.35-2.19) 
IgA (mg/ml) 1.11 4.93 (1.80-7.76) 3.68 (0.67-4.92) 0.72 (0.53-0.97) 0.65 (0.28-1.24) 
      
LPS (EU/ml)A NA 4.1 (1.6-13.3) 27.1 (8.7-125.9)* 14.3 (5.5-40.4) 28.3 (9.2-76.0) 
      
 
All protein concentrations and LPS activities have been adjusted for sample dilution based on the ratio of plasma to 
lavage urea concentrations. Comparison of healthy and mild asthmatic lavage protein concentrations was performed 
using the Mann-Whitney U test, with significance assumed at the 5% level. A: Lipopolysaccharide activities were 
determined using Limulus Amebocyte Lysate assay and reported in EU/ml. 
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Graphical Abstract 
 
The composition of the corona acquired by inhaled nanoparticles is modified in asthma and suggests 
depressed mucosal immunity even in mild airway disease 
